Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.4000-0.2300 (-4.97%)
At close: 04:00PM EDT
4.3101 -0.09 (-2.04%)
After hours: 05:57PM EDT
Advertisement

TG Therapeutics, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
212 554 4484
https://www.tgtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees286

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael S. Weiss Esq.Chairman, CEO & Pres2.07MN/A1966
Mr. Sean A. Power CPA, CPACFO, Corp. Sec. & Treasurer570.36kN/A1982
Dr. Owen A. O'ConnorChief Scientific OfficerN/AN/AN/A
Jenna BoscoSr. VP of Corp. CommunicationsN/AN/AN/A
Mr. Adam WaldmanChief Commercialization OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Corporate Governance

TG Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement